company background image
CMP

CompumedicsASX:CMP Stock Report

Market Cap

AU$69.1m

7D

-4.9%

1Y

-11.4%

Updated

22 Oct, 2021

Data

Company Financials
CMP fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance1/6
Financial Health4/6
Dividends0/6

CMP Overview

Compumedics Limited researches, develops, manufactures, sells, and distributes medical devices in Australia, the Asia Pacific, the Americas, Europe, and the Middle East.

Price History & Performance

Summary of all time highs, changes and price drops for Compumedics
Historical stock prices
Current Share PriceAU$0.39
52 Week HighAU$0.35
52 Week LowAU$0.58
Beta0.88
1 Month Change2.63%
3 Month Change1.30%
1 Year Change-11.36%
3 Year Change5.41%
5 Year Change-49.35%
Change since IPO-56.18%

Recent News & Updates

Aug 09
Compumedics (ASX:CMP) Will Want To Turn Around Its Return Trends

Compumedics (ASX:CMP) Will Want To Turn Around Its Return Trends

What are the early trends we should look for to identify a stock that could multiply in value over the long term...

Jun 10
Here's Why Compumedics (ASX:CMP) Has A Meaningful Debt Burden

Here's Why Compumedics (ASX:CMP) Has A Meaningful Debt Burden

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

May 06
Returns On Capital Signal Tricky Times Ahead For Compumedics (ASX:CMP)

Returns On Capital Signal Tricky Times Ahead For Compumedics (ASX:CMP)

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...

Shareholder Returns

CMPAU Medical EquipmentAU Market
7D-4.9%0.5%0.7%
1Y-11.4%-8.2%21.4%

Return vs Industry: CMP underperformed the Australian Medical Equipment industry which returned -8.2% over the past year.

Return vs Market: CMP underperformed the Australian Market which returned 21.4% over the past year.

Price Volatility

Is CMP's price volatile compared to industry and market?
CMP volatility
CMP Beta0.88
Industry Beta0.57
Market Beta1

Stable Share Price: CMP is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: CMP's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1987n/aDavid Burtonhttps://www.compumedics.com.au

Compumedics Limited researches, develops, manufactures, sells, and distributes medical devices in Australia, the Asia Pacific, the Americas, Europe, and the Middle East. It provides sleep diagnostics products, including Grael 4K PSG:EEG amplifiers; Somté PSG; Siesta 802, an ambulatory recording device; Grael PSG; and Somté, an investigative tool. The company also provides neurology diagnostics, such as ONsight A.V.S. for monitoring patient's home ambulatory studies; Grael 4K PSG:EEG amplifiers; Grael 4K-EEG amplifiers; Grael LT EEG System amplifiers; Neuvo 64-512 Channel LTM EEG monitoring systems; Xegis Forte EMG/EP; and Xegis G:NEO 2 Channel EMG/EP systems.

Compumedics Fundamentals Summary

How do Compumedics's earnings and revenue compare to its market cap?
CMP fundamental statistics
Market CapAU$69.09m
Earnings (TTM)AU$998.00k
Revenue (TTM)AU$35.74m

69.3x

P/E Ratio

1.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CMP income statement (TTM)
RevenueAU$35.74m
Cost of RevenueAU$16.58m
Gross ProfitAU$19.16m
ExpensesAU$18.16m
EarningsAU$998.00k

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.0056
Gross Margin53.61%
Net Profit Margin2.79%
Debt/Equity Ratio22.5%

How did CMP perform over the long term?

See historical performance and comparison

Valuation

Is Compumedics undervalued compared to its fair value and its price relative to the market?

69.27x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CMP's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CMP's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CMP is poor value based on its PE Ratio (69.3x) compared to the Australian Medical Equipment industry average (13.7x).

PE vs Market: CMP is poor value based on its PE Ratio (69.3x) compared to the Australian market (19.8x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CMP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CMP is good value based on its PB Ratio (3.1x) compared to the AU Medical Equipment industry average (4.6x).


Future Growth

How is Compumedics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.0%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Compumedics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Compumedics performed over the past 5 years?

-37.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CMP has a large one-off gain of A$955.0K impacting its June 30 2021 financial results.

Growing Profit Margin: CMP became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: CMP's earnings have declined by 37.5% per year over the past 5 years.

Accelerating Growth: CMP has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: CMP has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).


Return on Equity

High ROE: CMP's Return on Equity (4.5%) is considered low.


Financial Health

How is Compumedics's financial position?


Financial Position Analysis

Short Term Liabilities: CMP's short term assets (A$31.9M) exceed its short term liabilities (A$15.4M).

Long Term Liabilities: CMP's short term assets (A$31.9M) exceed its long term liabilities (A$1.0M).


Debt to Equity History and Analysis

Debt Level: CMP's debt to equity ratio (22.5%) is considered satisfactory.

Reducing Debt: CMP's debt to equity ratio has increased from 17.4% to 22.5% over the past 5 years.

Debt Coverage: CMP's debt is well covered by operating cash flow (26.5%).

Interest Coverage: CMP's interest payments on its debt are not well covered by EBIT (2.9x coverage).


Balance Sheet


Dividend

What is Compumedics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CMP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CMP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CMP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CMP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CMP's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average board tenure


CEO

David Burton (62 yo)

no data

Tenure

AU$249,967

Compensation

Dr. David Burton, Ph.D. founded Compumedics Ltd. in 1987 and serves as its Executive Chairman and Chief Executive Officer. Dr. Burton serves as Executive Chairman and Chief Executive Officer of Compumedics...


CEO Compensation Analysis

Compensation vs Market: Insufficient data to establish whether David's total compensation is reasonable compared to companies of similar size in the Australian market.

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: CMP's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Compumedics Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Compumedics Limited
  • Ticker: CMP
  • Exchange: ASX
  • Founded: 1987
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$69.094m
  • Shares outstanding: 177.16m
  • Website: https://www.compumedics.com.au

Location

  • Compumedics Limited
  • 30-40 Flockhart Street
  • Abbotsford
  • Victoria
  • 3067
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/22 07:03
End of Day Share Price2021/10/21 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.